lenalidomida genthon 5 mg
synthon bv - olanda - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
lenalidomida glenmark 10 mg
synthon hispania, s.l. - spania - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare
lenalidomida glenmark 15 mg
synthon hispania, s.l. - spania - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare
lenalidomida glenmark 25 mg
synthon hispania, s.l. - spania - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare
lenalidomida glenmark 5 mg
synthon hispania, s.l. - spania - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
sarclisa
sanofi winthrop industrie - isatuximab - mielom multiplu - agenți antineoplazici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
lenalidomida stada 10 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare
lenalidomida stada 15 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare
lenalidomida stada 2,5 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 2,5mg - imunosupresoare alte imunosupresoare
lenalidomida stada 20 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare